Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


DOV Confident Of Bicifadine "Residual Value" For Pain After Phase III Failure

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

DOV's analysis of a failed Phase III trial of its non-opioid analgesic bicifadine for chronic low back pain could be used to modify future and ongoing studies for the indication, according to the company

You may also be interested in...

DOV Initiates Second Bicifadine Phase III Trial In Revamped Population

DOV Pharmaceuticals' second Phase III clinical trial for its chronic lower back pain agent bicifadine will enroll a limited patient population, the company announced May 22

DOV drops ocinaplon

DOV is discontinuing development of its GABA receptor agonist ocinaplon "due to an unacceptable rate of liver enzyme elevations," the firm says Oct. 28. Ocinaplon, which had been in development for generalized anxiety disorder, had experienced several clinical holds, the most recent occurring in August (1Pharmaceutical Approvals Monthly September 2005, p. 15). "DOV will select a follow-on candidate from one of the backup compounds in its preclinical program," the company says. The firm also confirmed plans to submit an NDA for use of its non-opioid analgesic bicifadine in chronic low back pain during the first half of 2007. Phase II studies in osteoarthritis and neuropathic pain are slated to begin in the fourth quarter of 2005; an acute pain sNDA is slated for the fourth quarter of 2007...

FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011

Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts